Fundraising Fox
Oncosenx
Seattle, US · Founded 2017 · Delaware corporation · 5 known investors
Find your way into Oncosenx
Sign up to see every warm intro you have to Oncosenx
- Paths you didn't know you had: your email and LinkedIn already hold routes to the Oncosenx team. We find them for you
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
OncoSenX is a late-stage pre-clinical cancer therapeutics company developing treatments that target solid tumors based on transcriptional activity. Its system pairs a patented Proteo-Lipid Vehicle (PLV) delivery agent with plasmid DNA payloads that induce apoptosis in cancer cells while sparing adjacent cells.
Founders & leadership
Oncosenx was founded in 2017 by Matt Scholz.
Investors · 5
How we know: the VCSheet dataset · Not right? Tell us
How we know: Methuselah Foundation's portfolio page · Not right? Tell us
How we know: a partner's Signal profile · Not right? Tell us
How we know: a partner's Signal profile · Not right? Tell us
Reported raises · per SEC filings
Form D private placements$4.8M disclosed across 2 rounds · 2017–2021
▶$650KraisedAug 2021 · 8 investors · Other TechnologyRule 506(b)
- Eric GarciaExecutive Officer
- Stephen HilbertExecutive Officer
- Gary HudsonExecutive Officer, Director, Promoter
- John LewisExecutive Officer, Director, Promoter
- Matthew ScholzExecutive Officer, Director, Promoter
- Offering amount
- $5M
- Amount sold
- $650K
- First sale
- Jul 2021
- Incorporated
- Corporation, Delaware, 2017
- Federal exemptions
- 06b
▶$4.1MraisedApr 2020 · 62 investors · OtherRule 506(b)
- Matthew ScholzExecutive Officer, Director
- John LewisExecutive Officer, Director
- Gary HudsonDirector
- Offering amount
- $5.5M
- Amount sold
- $4.1M
- First sale
- Dec 2017
- Incorporated
- Corporation, Delaware, 2017
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Founder mafia
3 people who came through Oncosenx went on to found or lead other companies.
Related companies · 2
Companies working in the same space as Oncosenx.
Frequently asked questions
- What does Oncosenx do?
- OncoSenX is a late-stage pre-clinical cancer therapeutics company developing treatments that target solid tumors based on transcriptional activity. Its system pairs a patented Proteo-Lipid Vehicle (PLV) delivery agent with plasmid DNA payloads that induce apoptosis in cancer cells while sparing adjacent cells.
- Who founded Oncosenx?
- Oncosenx was founded by Matt Scholz in 2017.
- Who are Oncosenx's investors?
- Oncosenx's investors include Helios Capital, Methuselah Foundation, Methuselah Funds, ChainFund Capital, Invesco.
- How much funding has Oncosenx raised?
- Oncosenx has disclosed $4.8M raised across 2 rounds.
- Where is Oncosenx headquartered?
- Oncosenx is headquartered in Seattle, US.